Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like Cells

11 Nov 2011

Abstract excerpt

Overexpression of Notch receptors and ligands has been associated with various cancers and developmental disorders, making Notch a potential therapeutic target. Here, we report characterization of Notch1 monoclonal antibodies (mAb) with therapeutic potential. The mAbs generated against epidermal growth factor (EGF) repeats 11 to 15 inhibited binding of Jagged1 and Delta-like4 and consequently, signaling in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Developmental Biology and Gene Regulation
Share to Infectious Diseases and Mycology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22075160
DOI: 10.1158/1535-7163.mct-11-0508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like CellsPMID 22075160Read ↗

A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.Semantic proximity Read ↗

Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 ReceptorSemantic proximity Read ↗

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).Semantic proximity Read ↗

A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.Semantic proximity Read ↗

Study on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like CellsSemantic proximity Read ↗

Study on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like CellsStudy on Functional Monoclonal Antibodies of Anti-Human Uterine Sarcoma Stem Cell-Like CellsSemantic proximity Read ↗

Heterogeneity of breast cancer stem cells as evidenced with <scp>N</scp>otch‐dependent and <scp>N</scp>otch‐independent populationsSemantic proximity Read ↗

Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignanciesSemantic proximity Read ↗

Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.Semantic proximity Read ↗

Notch1 induces epithelial-mesenchymal transition and the cancer stem cell phenotype in breast cancer cells and STAT3 plays a key role.Semantic proximity Read ↗

S1-5: Modulation of Cancer and Stem Cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine Therapy for Early Stage ER+ Breast Cancer.Semantic proximity Read ↗

Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.